Announcement • May 30
Tempus AI, Inc. Receives Fda Approval for Tumor Only xT CDx Enabling Migration of Its Entire Dna Solid Tumor Portfolio Tempus AI, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted approval for a tumor-only indication for its xT CDx next-generation sequencing platform. With this expanded label, Tempus is the first laboratory to hold FDA companion diagnostic (CDx) approval for both tumor-only and tumor-normal comprehensive genomic profiling. Tempus xT CDx is a 648-gene tissue-based assay intended for molecular profiling of all solid tumor malignancies. It also serves as a companion diagnostic to identify colorectal cancer patients who may benefit from targeted therapies, specifically Erbitux (cetuximab) and Vectibix (panitumumab). While xT CDx previously required a patient’s matched normal sample, this regulatory milestone allows the test to run as a tumor-only assay when a matched normal specimen (blood or saliva) is not viable or available. This approval paves the way for Tempus to migrate its entire DNA solid tumor portfolio to FDA-approved assays priced under its current ADLT (Advanced Diagnostic Laboratory Test) pricing. xT CDx is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes in patients with previously diagnosed solid malignant neoplasms. The assay uses DNA isolated from Formalin-Fixed Paraffin Embedded (FFPE) tumor tissue specimens and, when available, patient-matched blood or saliva specimens. Additionally, the device detects microsatellite instability (MSI) status based on a genomic signature from the tumor specimen only. The test is intended as a companion diagnostic (CDx) to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table in accordance with the approved therapeutic product labeling. Additionally, xT CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product. Announcement • May 29
Tempus AI Upgrades Its Smart Physician Platform Hub With Next-Generation Agentic AI Architecture To Streamline Clinical Workflows Tempus AI, Inc. announced a major technological upgrade to Tempus Hub, its AI-enabled smart physician platform. Tempus is making available its advanced, next-generation generative AI clinical co-pilot directly in Hub to power an agent-first experience for healthcare providers, allowing them to integrate the benefits of large language models and generative AI capabilities with their diagnostic results to better treat cancer patients. This upgrade connects Tempus’ most advanced agentic AI capabilities directly with real-time patient data inside the Hub environment, scaling how providers utilize, interpret, and act upon complex diagnostic insights. Hub is a secure, AI-enabled platform that delivers actionable patient insights at the point of care. The platform provides seamless access to Tempus test orders and results, including guideline-matched therapies, treatment resistance insights, clinical trial opportunities, and longitudinal biomarker tracking for every patient. This new architecture introduces an advanced layer of agentic AI-enabled proactive intelligence. Key features rolling out to users include: Proactive AI Patient Genomic Insights: Hub can now proactively generate AI patient overviews and integrate deeper AI thinking applied to patients’ Tempus genomic results in the Hub summary page. Next-Step Documentation Generation: The platform is expanding to help users instantly generate patient-specific documentation, such as prior authorizations and patient messages, directly pulling in their Tempus data. Future Iterations of the Platform: Connecting Tempus Genomics Results with Tempus' Longitudinal Patient Registry or HIE (Health Information Exchange) data to unlock even more complex GenAI workflows. These capabilities are only possible given the significant investments Tempus has made over the years in building the foundation to connect AI to healthcare data, including Edge, which allows for real-time connection to EHR data and other provider systems, Locker, which allows providers to store their data in a secure environment they control as part of this connectivity, and Air, which allows it to deploy AI models and algorithms in real time to deliver insights at the point of care. Announcement • May 28
Tempus Ai, Inc. Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology Tempus AI, Inc. announced a significant expansion of new indications to its AI-enabled Next platform ahead of the 2026 American Society of Clinical Oncology Annual Meeting. Next establishes a new category of real-time clinical intelligence—a departure from legacy retrospective analyses and generic EHR alerts—designed to facilitate the delivery of precision medicine. Tempus will showcase a landmark study at ASCO 2026, describing clinically meaningful improvements in rates of biomarker testing for early-stage non-small cell lung cancer (eNSCLC) after the implementation of Tempus Next. The multi-center prospective study evaluated the deployment of the Tempus Next AI-enabled clinical decision support system (AI-CDSS) across 662 eNSCLC patients at six diverse U.S. community health systems. The Next platform drove significant behavioral change and successfully closed critical care gaps by analyzing unstructured EHR data to identify patients who did not receive guideline-directed biomarker testing. Key findings from the study include: The implementation of real-time interventions delivered an absolute testing rate lift of +24% for ALK, +18% for EGFR, and +13% for PD-L1 within 90 days of pathologic diagnosis. The program translated testing directly into optimized therapy management, with 89% of treated patients receiving guideline-concordant therapy. The expanded platform will surface insights from patients across six new clinical scenarios in breast, colorectal, ovarian, prostate, and urothelial cancers. Next has introduced a suite of advanced intelligence capabilities that enable precision medicine teams to map patient experiences and develop targeted care gap programs that support their institution’s health equity initiatives. Recent Insider Transactions • May 27
Co-Founder recently sold US$984k worth of stock On the 19th of May, Eric Lefkofsky sold around 22k shares on-market at roughly US$44.07 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Eric has been a net seller over the last 12 months, reducing personal holdings by US$12m. Live News • May 27
Tempus AI Expands Clinical Platform With ArteraAI Prostate Test and Bristol Myers Squibb Collaboration Tempus AI launched the ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer, marking the first externally developed digital pathology algorithm offered clinically on its platform.
The CLIA-certified and CAP-accredited test integrates clinical and biopsy image data to estimate prostate cancer-specific mortality risk for roughly 25,000 newly diagnosed metastatic patients each year in the U.S.
The test is available as an add-on to Tempus’s existing solid tumor portfolio, and the company expanded its collaboration with Bristol Myers Squibb as part of its precision oncology efforts.
This move broadens Tempus AI’s test menu and shows that its platform can support third-party algorithms, which may matter to investors who focus on how extensible its technology is for clinical tools.
The expanded Bristol Myers Squibb collaboration also highlights ongoing interest from large biopharma partners, although investors still need to weigh execution risk around adoption of new tests and the regulatory and reimbursement environment for advanced diagnostics. Announcement • May 23
Tempus AI, Inc. Launches ArteraAI Prostate Test For Metastatic Patients Tempus AI, Inc. announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic test will be fully integrated into the Tempus platform, providing urologists and oncologists with a digital pathology solution that helps inform personalization of therapy intensity in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The ArteraAI Prostate Test (mHSPC) is the first externally developed digital pathology algorithm being made clinically available through the Tempus ecosystem. This AI-powered test assesses a patient’s clinical information and histopathology biopsy image to produce a personalized risk estimate of the patient’s likelihood of prostate cancer-specific mortality. This algorithmic insight addresses a significant gap in the treatment landscape for the approximately 25,000 patients newly diagnosed with metastatic prostate cancer in the U.S. each year. By combining Tempus’ genomic-based next-generation sequencing (NGS) assay results with Artera’s pathology-based AI results, clinicians gain a far more comprehensive assessment of a patient’s prostate cancer disease. Clinicians will be able to order the ArteraAI Prostate Test (mHSPC) as an add-on to Tempus’ solid tumor portfolio across all ordering modalities. By establishing this new digital pathology workflow with the ArteraAI Prostate Test, clinicians are given a differentiated tool to better stratify risk and tailor therapy, helping ensure that patients with advanced prostate cancer receive a personalized, evidence-based treatment plan from the very start of their care journey. Major Estimate Revision • May 12
Consensus EPS estimates fall by 23% The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -US$1.67 to -US$2.04 per share. Revenue forecast unchanged at US$1.59b. Life Sciences industry in the US expected to see average net income growth of 12% next year. Consensus price target down from US$72.40 to US$67.20. Share price fell 13% to US$48.46 over the past week. Price Target Changed • May 11
Price target decreased by 7.2% to US$67.20 Down from US$72.40, the current price target is an average from 15 analysts. New target price is 39% above last closing price of US$48.46. Stock is down 23% over the past year. The company is forecast to post a net loss per share of US$2.04 next year compared to a net loss per share of US$1.41 last year. Announcement • May 07
Tempus AI, Inc. Increases Earnings Guidance for the Full Year 2026 Tempus AI, Inc. increased earnings guidance for the full year 2026. For the period, the company expects revenue in range of $1.59 billion to $1.60 billion, which represents ~25% annual growth. Reported Earnings • May 06
First quarter 2026 earnings: EPS misses analyst expectations First quarter 2026 results: US$0.70 loss per share (further deteriorated from US$0.40 loss in 1Q 2025). Revenue: US$348.1m (up 36% from 1Q 2025). Net loss: US$125.9m (loss widened 85% from 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 34%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Announcement • Apr 21
Tempus AI, Inc. to Report Q1, 2026 Results on May 05, 2026 Tempus AI, Inc. announced that they will report Q1, 2026 results on May 05, 2026 Announcement • Apr 14
Tempus AI, Inc. Launches Automated Active Follow-Up Service Tempus AI, Inc. announced the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an active follow-up track. This integrated workflow provides clinicians with ongoing therapy monitoring and context-aware notifications seamlessly delivered through Hub, Tempus’ secure, AI-enabled physician portal. Because NCCN guidelines, FDA approvals, and patient context can all evolve rapidly, an initial genomic report can quickly become outdated relative to a patient’s ongoing treatment journey. Tempus is addressing this challenge by automatically surfacing updated therapy recommendations when clinical guidelines change or new therapeutic options emerge—all without requiring a new patient sample. This ensures that patient insights remain as current as the science, supporting evidence-based decision-making throughout the patient’s treatment journey. Price Target Changed • Apr 13
Price target decreased by 8.4% to US$72.40 Down from US$79.07, the current price target is an average from 15 analysts. New target price is 57% above last closing price of US$45.98. Stock is up 6.6% over the past year. The company is forecast to post a net loss per share of US$1.60 next year compared to a net loss per share of US$1.41 last year. Announcement • Apr 08
Tempus AI, Inc., Annual General Meeting, May 21, 2026 Tempus AI, Inc., Annual General Meeting, May 21, 2026. Announcement • Apr 01
Tempus AI, Inc. Announces Results from ALERT Trial Tempus AI, Inc. announced results from the ALERT (Addressing undertreatment and heaLth Equity in aortic stenosis and mitral regurgitation using an integrated ehR plaTform) trial, which were recently presented at the American College of Cardiology’s 75th Annual Scientific Session & Expo. The study, conducted in collaboration with Medtronic, found that automated electronic clinician notifications (ECNs) integrated into the electronic health record (EHR) significantly improve the timely evaluation and treatment of patients with significant aortic stenosis (AS) and mitral regurgitation (MR). Valvular heart disease is a leading cause of morbidity and mortality, yet it remains frequently undertreated. For patients with untreated symptomatic severe AS, mortality approaches 50% within just two years. Similarly, untreated severe MR carries a median survival of only five years. The ALERT trial was designed to determine if automated, AI-driven alerts could bridge this critical gap in care delivery. By leveraging the Tempus Next platform, which applies natural language processing to accurately extract findings from echocardiogram reports, the trial enabled real-time detection of significant disease and automatically delivered notifications with site-specific guideline-based care notifications directly to providers. The ALERT trial included 765 clinicians and 2,016 echocardiograms across five U.S. health systems and 35 hospitals. The study met its primary endpoint, demonstrating that automated ECN alerts were superior to usual care in a win ratio analysis (win ratio 1.27; P = .007), meaning patients in the alert group were 27% more likely to be evaluated by the multidisciplinary heart team or receive a valve intervention than those in the usual care group. By delivering actionable data directly to providers, the system facilitated a 40% relative increase in life-saving valve procedures (13.4% vs. 9.6%) and a 27% increase in multidisciplinary heart team evaluations (22.7% vs. 17.9%) within just 90 days. These alerts effectively reduced clinical inertia, prompting earlier specialist referrals and ensuring patients received interventions within established benchmarks for timely care. Beyond clinical efficiency, a central objective of the ALERT trial was to confront the persistent disparities that leave women, older adults, racial and ethnic minorities, and rural residents at higher risk of being undertreated. These findings suggest that EHR-integrated clinical decision support can serve as a powerful, scalable 'safety net,' standardizing care delivery to help ensure high-risk findings receive timely action regardless of a patient's demographics or care setting. While the ALERT trial was conducted in collaboration with Medtronic, the automated clinician notifications were designed to be device-agnostic to promote standardized care delivery, without requiring providers to use specific Medtronic devices for recommended evaluations or interventions. Announcement • Mar 11
Tempus Ai, Inc. Announces the Publication of A New Study in Jco Precision Oncology Tempus AI, Inc. announced the publication of a new study in JCO Precision Oncology highlighting how advanced features of comprehensive genomic profiling (CGP) expand treatment options for cancer patients in community oncology settings. The study, conducted in collaboration with The Oncology Institute (TOI), reveals that features such as tumor-normal matched sequencing, RNA sequencing, and liquid biopsy reflex identify actionable findings that are missed by more limited standard in-network testing. While organizations like ASCO and the NCCN strongly advocate for CGP to guide precision therapies, current guidelines often lack specificity regarding the exact composition or essential features required within these panels. This research demonstrates that CGP value extends far beyond simple panel size, highlighting the utility of advanced testing features to more fully capture clinically relevant findings. In the study, 12% (approximately 1 in 8) of patients across the pilot and expanded cohorts had potentially actionable findings associated with an approved therapy identified solely through advanced Tempus features—such as tumor-normal matching, RNA sequencing, and liquid biopsy reflex testing—that would otherwise have been missed by less comprehensive tests. Price Target Changed • Mar 03
Price target decreased by 11% to US$77.50 Down from US$86.71, the current price target is an average from 14 analysts. New target price is 51% above last closing price of US$51.40. Stock is down 2.5% over the past year. The company is forecast to post a net loss per share of US$1.58 next year compared to a net loss per share of US$1.41 last year. Recent Insider Transactions Derivative • Mar 03
Chief Financial Officer notifies of intention to sell stock James Rogers intends to sell 14k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of March. If the sale is conducted around the recent share price of US$53.25, it would amount to US$723k. Since March 2025, James' direct individual holding has increased from 17.76k shares to 24.65k. Company insiders have collectively sold US$19m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Mar 03
Consensus EPS estimates fall by 32%, revenue upgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from US$1.58b to US$1.59b. Forecast EPS reduced from -US$1.27 to -US$1.67 per share. Life Sciences industry in the US expected to see average net income growth of 17% next year. Consensus price target down from US$85.69 to US$80.14. Share price fell 6.9% to US$53.31 over the past week. Recent Insider Transactions • Feb 26
Executive VP recently sold US$1.1m worth of stock On the 20th of February, Andrew Polovin sold around 19k shares on-market at roughly US$59.77 per share. This transaction amounted to 58% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$19m more than they bought in the last 12 months. Breakeven Date Change • Feb 25
No longer forecast to breakeven The 14 analysts covering Tempus AI no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$17.0m in 2028. New consensus forecast suggests the company will make a loss of US$53.4m in 2028. Recent Insider Transactions Derivative • Feb 22
Executive VP notifies of intention to sell stock Andrew Polovin intends to sell 11k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of February. If the sale is conducted around the recent share price of US$59.96, it would amount to US$657k. Since March 2025, Andrew's direct individual holding has decreased from 15.95k shares to 14.22k. Company insiders have collectively sold US$106m more than they bought, via options and on-market transactions in the last 12 months. Announcement • Feb 18
Tempus AI, Inc. Announces Novel Pan-Cancer HRD-RNA Algorithm Tempus AI, Inc. announced the launch of its new HRD-RNA algorithm. This next-generation model represents a significant improvement in identifying Homologous Recombination Deficiency (HRD), providing a more robust, functional assessment of tumor biology compared to traditional static DNA-based assays. Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model designed to identify patients likely to respond to platinum-based chemotherapy or PARP inhibitors. Unlike traditional DNA tests that analyze static "genomic scars"--which may persist even after a patient develops drug resistance--this RNA-based approach provides a dynamic, real-time assessment of a tumor's functional status. By analyzing gene expression rather than structural DNA damage, the algorithm can detect HRD in patients and cancer types where genomic scarring is rare or difficult to identify. This advanced methodology allows the model to capture HRD status in patients who might be missed by DNA-based assays, significantly expanding the population that can be identified for potentially life-saving therapies. A real-world validation study demonstrates that HRD-RNA positive metastatic pancreatic patients treated with first line platinum-based regimens showed a significant reduction in mortality risk compared to those receiving non-platinum first line therapies. These findings, including the complete supporting data, will be published later this year. HRD-RNA is currently available for research use only in the detection of HRD status within solid tumor patient populations and for the identification of patients likely to respond to platinum regimens or PARP inhibitor therapy. Clinical availability is expected later this year. Announcement • Feb 10
Tempus AI, Inc. to Report Q4, 2025 Results on Feb 24, 2026 Tempus AI, Inc. announced that they will report Q4, 2025 results on Feb 24, 2026 Announcement • Jan 27
Tempus Ai, Inc. Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers Tempus AI, Inc. announced results from a new study demonstrating that its algorithmic test, Immune Profile Score (IPS), more accurately predicts outcomes for patients receiving immune checkpoint inhibitors (ICIs) than conventional biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI), and PD-L1. IPS is a multimodal biomarker that combines known and novel clinical and immune-related biomarkers from DNA and RNA analysis to predict a patient's response to ICI-based therapy. The new clinical validation results demonstrate that IPS consistently outperforms conventional biomarkers, highlighting its potential to change the way physicians can identify patients most likely to benefit from immunotherapy. In four independent validation cohorts of pan-cancer metastatic solid organ cancer patients, IPS was shown to be a more accurate predictor of ICI outcomes (HR=0.45) than TMB, MSS, and PD-L1, demonstrating prognostic utility that is independent of those conventional biomarkers. IPS identified 13% of patients with microsatellite stable colorectal cancer who demonstrated strong real-world overall survival with ICI treatment (HR=0.2), indicating that ICI immunotherapy may be a viable option for a key patient population that might have been overlooked with conventional biomarkers alone. Beyond colorectal cancer, the study's findings highlight how IPS could expand treatment options for patients with rare cancers. IPS classified 17% of patients with rare metastatic solid tumors as "IPS-High," despite these patients not falling within a cancer-specific FDA-approved ICI label. The significant difference in median real-world overall survival in "IPS High" versus "IPS-Low" patients (HR=0.26) shows that ICI could be a relevant and potentially life-saving option for patients that might otherwise be missed. The test is available as an add-on for clinicians ordering Tempus' xT (DNA) and xR (RNA) assays, helping to manage patients on immunotherapy by utilizing data already collected as part of a patient's standard sequencing. Announcement • Jan 21
Tempus AI, Inc. Announces the Launch of Paige Predict Tempus AI, Inc. announced the launch of Paige Predict, a suite of cutting-edge digital pathology applications that analyze hematoxylin and eosin (H&E) whole slide images to help inform testing decisions. The AI-powered solution is designed to predict the likely presence or absence of clinically actionable and relevant biomarkers directly from a single H&E slide, offering physicians insights even when tissue samples are insufficient for full molecular profiling. As the demand for next-generation sequencing (NGS) and immunohistochemistry (IHC) testing grows, so does the challenge of limited tissue availability. When a sample is "quantity not sufficient" (QNS), patients can face delays of days or weeks for testing results, waiting for repeat biopsies or alternative testing, ultimately prolonged uncertainty and potentially impacting treatment options. Paige Predict's ability to use an H&E image to identify biomarkers that are more or less likely to be present in the specimen can be used by clinicians to inform the sequence in which they will order confirmatory tissue-based tests, maximizing the likelihood of receiving an actionable result before exhausting tissue. Leveraging Tempus and Paige's intelligent digital pathology platform and proprietary AI products, Paige Predict identifies critical biomarker information from even scarce amounts of tissue and analyzes H&E images to predict the likelihood of 123 biomarkers and oncogenic molecular pathways in 16 cancer types, including NSCLC, prostate, breast, pancreatic, colorectal, and more. Results are automatically delivered with the clinical report to ordering physicians. Paige Predict was built using Paige's foundation model and a combined, multimodal cohort from Tempus and Paige, which contains de-identified data on over 200,000 patients. The model has been rigorously validated to demonstrate performance, generalizability and robustness across multiple, diverse datasets, including a large-scale cohort from Tempus. Breakeven Date Change • Dec 31
Forecast to breakeven in 2028 The 14 analysts covering Tempus AI expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$17.7m in 2028. Average annual earnings growth of 44% is required to achieve expected profit on schedule. Recent Insider Transactions Derivative • Dec 13
Chief Financial Officer notifies of intention to sell stock James Rogers intends to sell 20k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of December. If the sale is conducted around the recent share price of US$75.07, it would amount to US$1.5m. Since December 2024, James' direct individual holding has decreased from 60.06k shares to 27.47k. Company insiders have collectively sold US$265m more than they bought, via options and on-market transactions in the last 12 months. Announcement • Dec 09
Tempus AI, Inc. Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium Tempus AI, Inc. announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS). The meeting takes place December 9-12 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Tempus will highlight its latest scientific and clinical research findings via ten poster presentations: Integrative Modeling of Multimodal Real-World Data for Improved Risk Stratification of First-Line CDK4/6 inhibitor plus endocrine treatment and identify predictors of response. This study demonstrated that multimodal real-world data collected during routine care can provide valuable insights into the biology of response to CDK4/6 inhibitors in patients with metastatic breast cancer and help improve patient stratification. Distinct Transcriptional and Immunosuppressive Microenvironment Signatures in PIK3CA-mutant Hormone Receptor Positive (HR+)/HER2- Metastatic Breast Cancer (MBC). Date/Time: December 10, 2025, 12:30 p.m. - 2:30 p.m. CDT. Presentation Number: PS1-11-08. Summary: This study compared transcriptomic and immune profiles in HR+/HER2- metastatic breast cancer across wild-type, PIK3CA-mutants, ESR1-mutant, and co-mutant groups. SFRP2 downregulation was specific to ESR1-mutant tumors, while SCGB2A2 was robustly upregulated in PIK3CA- mutant and co-mutant tumors, suggesting its potential as a diagnostic and therapeutic target. Immune analysis revealed increased M2 macrophages and regulatory T cells in PIK3CA- mutualant and co-mutant tumor, with the most pronounced immunosuppressive microenvironment in PIK3CA-Mutant cases. A notable percentage of patients with localized and de novo metastatic disease displayed TMB high status and/or PD-L1 positivity. Additionally, TMB-high and PD-L1 positive patients with de novo metastatic disease treated with first-line chemotherapy or anti-HER2 therapy had significantly worse real-world overall survival (rwOS), suggesting a potential therapeutic benefit of incorporating immunotherapy into the treatment paradigm, in both localized and metastatic disease settings. Furthermore, observed ethnic HLA polymorphisms in the cohort may contribute to differences in outcomes and could potentially guide the development of population-specific immunotherapeutic strategies. Real-World Data (RWD) Outcome Analysis of ESR1 Mutation Emergence in HR+/HER2 - Metastatic Breast Cancer through the Continuum of Standard of Care Hormonal Therapy. Date/Time: Friday, December 12, 2025, 12:30p.m. - 2:00 p.m. CDT, Presentation Number: PS5-05-02. Summary: This large multimodal RWD outcome analysis from longitudinal molecular surveillance testing (xF) in HR+/HER2. mBC patients treated with AI+CDK4/6 inhibitor (ER)-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer. Date/Time: December 12, 2025, 12; 12:30 p.m., 2:00 p.m., CDT and Presentation Number: PS5.05-02; Summary: This large multimodAL RWD outcome analysis from longitudinal Molecular surveillance testing (xF)in HR+/HER2- mBC pts treated with AI+ CDK4/6 inhibitors treated with AI+CDK 4/6 inhibitor plus end endocrine treatment and resistance. These insights are essential for pinpointing patient populations who may benefit from novel therapies and for optimizing treatment strategies to ultimately improve outcomes for those with advanced disease. Recent Insider Transactions Derivative • Nov 25
Executive VP notifies of intention to sell stock Andrew Polovin intends to sell 13k shares in the next 90 days after lodging an Intent To Sell Form on the 24th of November. If the sale is conducted around the recent share price of US$70.29, it would amount to US$905k. Since December 2024, Andrew's direct individual holding has decreased from 97.41k shares to 27.09k. Company insiders have collectively sold US$362m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Nov 23
Co-Founder recently sold US$9.1m worth of stock On the 20th of November, Eric Lefkofsky sold around 130k shares on-market at roughly US$69.48 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Eric has been a net seller over the last 12 months, reducing personal holdings by US$216m. New Risk • Nov 17
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$204m Forecast net loss in 3 years: US$18m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). Significant insider selling over the past 3 months (US$5.5m sold). Price Target Changed • Nov 10
Price target increased by 11% to US$91.33 Up from US$82.50, the current price target is an average from 12 analysts. New target price is 28% above last closing price of US$71.56. Stock is down 3.0% over the past year. The company is forecast to post a net loss per share of US$1.50 next year compared to a net loss per share of US$6.23 last year. Reported Earnings • Nov 06
Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2025 results: US$0.46 loss per share. Revenue: US$334.2m (up 85% from 3Q 2024). Net loss: US$80.0m (loss widened 5.5% from 3Q 2024). Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates by 12%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US. Price Target Changed • Nov 05
Price target increased by 10% to US$85.42 Up from US$77.55, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of US$84.49. Stock is up 90% over the past year. The company is forecast to post a net loss per share of US$1.35 next year compared to a net loss per share of US$6.23 last year. Announcement • Oct 21
Tempus AI, Inc. to Report Q3, 2025 Results on Nov 04, 2025 Tempus AI, Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 04, 2025 Price Target Changed • Oct 21
Price target increased by 9.3% to US$80.25 Up from US$73.45, the current price target is an average from 12 analysts. New target price is 13% below last closing price of US$92.45. Stock is up 99% over the past year. The company is forecast to post a net loss per share of US$1.32 next year compared to a net loss per share of US$6.23 last year. Announcement • Sep 23
Tempus AI, Inc. Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS in Vitro Diagnostic Device Tempus AI, Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device. xR IVD will be offered as a life science tool to support drug development programs. RNA sequencing captures a large array of biological information and offers deeper insights into the mechanisms of diseases, including enhanced fusion detection. RNA analysis is increasingly an important tool in research and development because it can identify molecular pathways and networks that are directly involved in disease progression. The Tempus xR IVD assay is a qualitative next generation sequencing-based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology for detection of rearrangements in two genes, using RNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens from patients with solid malignant neoplasms. Information provided by xR IVD is intended to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed malignant neoplasms. Results from xR IVD are not intended to be prescriptive or conclusive for labeled use of any specific therapeutic product. The FDA authorization further solidifies Tempus as a one-stop-shop for precision medicine solutions. Collaborators can leverage Tempus' comprehensive collection of intelligent diagnostics and growing multimodal data that supports therapeutic innovation. xR IVD is one of the many solutions Tempus is applying to advance oncology therapeutic research and development. Announcement • Sep 11
Tempus AI, Inc. Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device Tempus AI, Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enhancing the device's capabilities for cardiac MR image analysis. Tempus Pixel provides advanced viewing and automated reporting of cardiac MR images, improving efficiency and accuracy in flow visualization, functional analysis, and tissue characterization. AI-enabled radiology, like Tempus Pixel, enhances medical imaging by rapidly analyzing scans, highlighting subtle abnormalities, and generating consistent, actionable insights. By improving accuracy and efficiency, it empowers clinicians to make faster, more informed decisions and deliver personalized patient care. Unlike conventional MR images that show only brightness differences, T1 and T2 maps provide precise numerical values to cardiac tissue characteristics, helping clinicians detect conditions such as fibrosis, inflammation, or edema, that may otherwise go undetected. With its newly cleared functionality, Tempus Pixel can now generate T1 and T2 inline map directly from raw MRI data, even when the scanner itself does not produce them, calculating values at every pixel across the image to create detailed DICOM maps for comprehensive tissue assessment. Tempus has developed and deployed a suite of advanced algorithms across radiology and pathology, helping physicians deliver more precision, personalized care. Its strategic acquisitions have further strengthened its footprint in these fields. In 2022, Tempus acquired Arterys, incorporating its AI-powered tools for analyzing imaging data--ranging from lung CT scans and chest X-rays to cardiac MRIs-- into Tempus' platform. Most recently, Tempus acquired Paige, an AI company specializing in digital pathology, bringing a proprietary dataset of almost 7 million clinically annotated, de-identified pathology slides to accelerate Tempus' efforts. Announcement • Sep 09
Tempus AI, Inc. Announces New Study in JCO Precision Oncology Validating PurIST Algorithm for Enhanced Therapy Selection in Pancreatic Cancer Tempus AI, Inc. announced the publication of a study in JCO Precision Oncology validating the clinical utility of the company's PurIST®? algorithmic diagnostic. The study provides the largest real-world evidence to date supporting the integration of PurIST into routine clinical care for patients with advanced PDAC, with the aim of informing first-line chemotherapy selection and improving patient outcomes. Pancreatic cancer remains one of the most lethal malignancies, with limited therapeutic options and a five-year survival rate of just 12%. For patients with advanced, unresectable PDAC, the two most common first-line chemotherapy regimens, FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP), have shown variable efficacy, and clinicians have lacked robust biomarkers to guide optimal therapy selection. To address this challenge, Tempus collaborated with GeneCentric to develop and deploy PurIST, a clinically validated, RNA-based algorithm test that classifies PDAC tumors as either "classical" or "basal" subtypes. The Tempus-led study analyzed a real-world cohort of 931 patients with advanced PDAC, using the Tempus xR RNA sequencing platform to assign PurIST subtypes. Patients were treated with either first-line FFX or GnP, and clinical outcomes were assessed according to PurIST classification. The study's findings establish PurIST as both a prognostic and predictive biomarker, enabling clinicians to personalize first-line therapy for advanced PDAC patients and maximize the likelihood of improved survival. Prognostic Value: Among patients treated with FFX (N=536), those with the classical subtype had a significantly longer median overall survival (OS) of 11.8 months, compared to 7.0 months for basal subtype patients (Hazard Ratio [HR]=1.86; p; Predictive Value: In patients with the classical subtype and good performance status (ECOG 0 or 1, N=311), treatment with FFX was associated with a 33% relative risk reduction in death compared to GnP (HR=0.67; p<0.009). No comparable benefit was observed in basal subtype patients. Recent Insider Transactions • Aug 29
Independent Director recently sold US$1.5m worth of stock On the 26th of August, Theodore Leonsis sold around 20k shares on-market at roughly US$75.83 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$3.1m. Insiders have been net sellers, collectively disposing of US$351m more than they bought in the last 12 months. Recent Insider Transactions Derivative • Aug 27
Independent Director notifies of intention to sell stock Theodore Leonsis intends to sell 20k shares in the next 90 days after lodging an Intent To Sell Form on the 26th of August. If the sale is conducted around the recent share price of US$75.83, it would amount to US$1.5m. Since December 2024, Theodore's direct individual holding has increased from 676.00 shares to 89.46k. Company insiders have collectively sold US$349m more than they bought, via options and on-market transactions in the last 12 months. Announcement • Aug 23
Tempus AI, Inc. (NasdaqGS:TEM) acquired Paige.AI, Inc. in a transaction valued at $81.2 million. Tempus AI, Inc. (NasdaqGS:TEM) acquired Paige.AI, Inc. in a transaction valued at $81.2 million on August 22, 2025. The consideration consists of $81.25 million, which is being paid predominantly in Tempus common stock, as well as Tempus’ assumption of Paige’s remaining commitment under its existing Microsoft Azure cloud services agreement. Morgan Stanley (NYSE:MS) acted as financial advisor to Paige.AI, Inc.
Tempus AI, Inc. (NasdaqGS:TEM) completed the acquisition of Paige.AI, Inc. on August 22, 2025. Recent Insider Transactions • Aug 17
Independent Director recently sold US$3.1m worth of stock On the 13th of August, Theodore Leonsis sold around 44k shares on-market at roughly US$69.90 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$345m more than they bought in the last 12 months. Reported Earnings • Aug 10
Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Second quarter 2025 results: US$0.25 loss per share (improved from US$6.86 loss in 2Q 2024). Revenue: US$314.6m (up 90% from 2Q 2024). Net loss: US$42.8m (loss narrowed 92% from 2Q 2024). Revenue exceeded analyst estimates by 5.7%. Earnings per share (EPS) also surpassed analyst estimates by 45%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Announcement • Aug 09
Tempus AI, Inc. has filed a Follow-on Equity Offering in the amount of $500 million. Tempus AI, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.
Security Name: Class A Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Announcement • Aug 08
Tempus AI, Inc. Increases Earnings Guidance for the Full Year 2025 Tempus AI, Inc. increased earnings guidance for the full year 2025. For the period, the company now expects revenue of approximately $1.26 billion for the consolidated business, which represents approximately 82% annual growth. Announcement • Aug 02
Bragar Eagel & Squire, P.C. Files A Class Action Lawsuit Against Tempus Ai, Inc Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Tempus AI, Inc. in the United States District Court for the Northern District of Illinois on behalf of all persons and entities who purchased or otherwise acquired Tempus securities between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. According to the complaint, defendants failed to disclose: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of "round-tripping" capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable "pass-through payment" via a joint agreement between it, the Company and Pathos AI; and (5) the foregoing issues revealed weakness in core operations and revenue prospects. The complaint alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued a report on Tempus that raised numerous red flags over Tempus' management, operations and financial reporting. The Spruce Point Report scrutinized Tempus on an array of issues, including: (1) defendant Eric Lefkofsky and his associates have a history cashing out of companies before public shareholders incur losses or lackluster returns; (2) Tempus' actual AI capabilities are overstated; (3) board members and other executives have been associated with troubled companies that restated financial results; (4) signs of aggressive accounting and financial reporting; (4) issues with the AstraZeneca and Pathos AI deal that merit scrutiny; and (5) the Company's recent financial guidance reveals weakness in core operations. On this news, the price of Tempus common stock fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025. Announcement • Jul 22
Tempus AI, Inc. to Report Q2, 2025 Results on Aug 08, 2025 Tempus AI, Inc. announced that they will report Q2, 2025 results on Aug 08, 2025 Recent Insider Transactions Derivative • Jun 18
Executive VP notifies of intention to sell stock Erik Phelps intends to sell 51k shares in the next 90 days after lodging an Intent To Sell Form on the 16th of June. If the sale is conducted around the recent share price of US$71.28, it would amount to US$3.7m. Since December 2024, Erik's direct individual holding has decreased from 124.07k shares to 69.26k. Company insiders have collectively sold US$342m more than they bought, via options and on-market transactions in the last 12 months. Announcement • Jun 01
Tempus Ai, Inc. Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using Its Novel Foundation Model Tempus AI, Inc. announced the launch of its Fuses program. This initiative will harness Tempus' proprietary dataset to generate valuable insights for both patient care and research, combining the power of its data and machine learning capabilities to develop an AI enabled-diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality. Over the past decade, Tempus has built a multimodal data library of over 40 million research records, including more than 1.5 million records with matched clinical data linked with genomic information, 2 million records with imaging data, and approximately 300,000 records with genomic and whole transcriptomic data. The scale and size of this data library will allow the company to uncover groundbreaking discoveries that were previously out of reach. Fuses will accelerate Tempus' comprehensive testing portfolio, expanding its suite of AI-enabled diagnostics. Insights from Fuses will be developed into clinically validated algorithmic diagnostics that may enable highly personalized care, such as identifying patients unlikely to respond to approved therapies or those at risk of severe treatment-related events. Tempus has already begun this work with last year's launch of its Immune Profile Score (IPS) a multimodal biomarker that can be used as a prognostic indicator for adult patients with metastatic pan-solid tumors eligible for immune checkpoint inhibitor (ICI)-based therapy. The foundational model behind Fuses is learning generalizable rules determining prognosis and drug benefit in real-world practice. With the goal of furthering researchers' understanding of why certain clinical trials fail, identify new indications for investigational drugs, optimize trial design, and uncover combination therapies to broaden patient benefit. By revealing biomarker rules, the model may also surface mechanisms of drug response and resistance to inspire a new generation of companion diagnostics and therapeutic research. Recent Insider Transactions • May 25
Co-Founder recently sold US$1.1m worth of stock On the 20th of May, Eric Lefkofsky sold around 17k shares on-market at roughly US$63.21 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$82m. Eric has been a net seller over the last 12 months, reducing personal holdings by US$206m. Recent Insider Transactions Derivative • May 21
Chief Financial Officer notifies of intention to sell stock James Rogers intends to sell 12k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of May. If the sale is conducted around the recent share price of US$63.74, it would amount to US$746k. Since June 2024, James' direct individual holding has decreased from 118.06k shares to 17.76k. Company insiders have collectively sold US$339m more than they bought, via options and on-market transactions in the last 12 months. Board Change • May 14
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Independent Director Jennifer Doudna was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Major Estimate Revision • May 13
Consensus EPS estimates fall by 27% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$1.29 to -US$1.64 per share. Revenue forecast unchanged at US$1.25b. Life Sciences industry in the US expected to see average net income growth of 13% next year. Consensus price target broadly unchanged at US$62.00. Share price rose 16% to US$62.69 over the past week. Reported Earnings • May 07
First quarter 2025 earnings: EPS and revenues exceed analyst expectations First quarter 2025 results: US$0.40 loss per share (improved from US$1.47 loss in 1Q 2024). Revenue: US$255.7m (up 75% from 1Q 2024). Net loss: US$68.0m (loss narrowed 27% from 1Q 2024). Revenue exceeded analyst estimates by 3.1%. Earnings per share (EPS) also surpassed analyst estimates by 8.1%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Announcement • May 07
Tempus AI, Inc. Increases Earnings Guidance for Full Year 2025 Tempus AI, Inc. increased earnings guidance for full year 2025. The company now expects full year revenue of approximately $1.25 billion for the consolidated Tempus and Ambry Genetics business, which represents approximately 80% annual growth. Announcement • May 06
Tempus Ai, Inc. Announces Notetaker, Its Ai-Powered Clinical Assistant for Psychiatry Tempus AI, Inc. has announced the launch of Notetaker, an AI-powered clinical assistant to aid psychiatrists in generating progress notes. Notetaker, which is available in Tempus Hub, aggressively records patient sessions to generate transcripts and clinical notes that can be seamlessly stored in patients' electronic health records. Notetaker complements Tempus' existing mental health platform designed to support clinicians in delivering personalized care. It joins other precision medicine solutions, including the Tempus nP pharmacogenomic test and PRO, the company's patient reported outcome solution. Key features of Notetaker include: Recording Sessions: Notetaker effortlessly transcribes and processes the session in real-time, capturing key details with precision, including specialized psychiatric terminology and medications. Generating Notes: At the end of each session, a clinical note is automatically created, highlighting essential information such as symptoms, progress, and action plans for quick review. Refining During Review: Clinicians can easily review and modify the autogenerated note using the Magic Edit features to adjust formatting or details according to their preferences. Care Gap Notification: Notetaker identifies and helps close care gaps with real-time pharmacogenomic insights for medications under consideration. Notetaker is capable of understanding more than 30 languages, including English, Spanish, and Chinese. It can seamlessly recognize language switching without the need to set a specific language in advance. With adjustable settings tailored for telehealth, in-person sessions, and dictation, Notetaker adapts to various environments for adequate audio capture. While providers are responsible for obtaining all necessary consents before recording sessions, Notetaker supports HIPAA-compliant data transfer and storage. Announcement • May 01
Tempus AI, Inc. Time Network Expands Support of Phase I Clinical Trials to Accelerate Activation and Enrollment Tempus AI, Inc. is leveraging its TIME Network to expand its support in phase I clinical trials. Since its inception in 2019, TIME has supported the rapid patient identification and site activation of clinical trials, bringing cutting-edge trials to patients in communities across the U.S. To further expand its support of phase I trials, Tempus has formed the TIME Precision Network, a group of investigators leading the phase I study platform with a focus on activating and enrolling quickly across over 40 phase I-capable research centers. Most recently, TIME enrolled the First Patient In (FPI) for multiple phase I trials. The TIME Network is powered to efficiently enroll patients within its participating data-integrated site base, in which patients are identified and matched to trials and sites are activated within days or weeks. At the Taylor Cancer Research Center (TCRC), Tempus activated the site in approximately two weeks for the Nimbus 9216-101 study, and enrolled its first patient within one month of site activation. For the Pathos P300-02-001 study, Tempus screened and enrolled the trial's first and second patients at Nebraska Cancer Specialists and Oncology Consultants within weeks. Announcement • Apr 28
Tempus AI, Inc. Introduces Loop, an AI-Powered Target Discovery and Validation Platform Tempus AI, Inc. announced Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is Tempus' proprietary approach to novel target identification that integrates real-world patient data (RWD) with human-derived biological models and CRISPR-screens, all leveraging AI to rapidly uncover insights for pre-clinical therapeutic development. One of the biggest industry challenges has been translating promising preclinical experiments into treatments that can benefit patients. Conventional approaches in target discovery and validation rely on cell lines or animal models, which may not be reliable representations of human tumors. Loop's approach is uniquely powerful because it leverages Tempus' rich RWD to identify patient subpopulations with similar clinical, pathologic, and molecular patterns, followed by use of systems biological approaches to help reveal novel target genes and multimodal signatures. These signatures allow Tempus to seamlessly map patient subcohorts to relevant patient-derived organoids (PDOs), which the company has been expanding for years. By ensuring continuity between RWD and PDOs, Tempus can validate targets using high-throughput functional screens in models that more closely reflect patient attributes. This seamless integration--RWD to PDO and back--can help to enable rapidhesis generation and testing in the most relevant disease models, accelerating target discovery and validation. Tempus has already deployed its Loop platform to prioritize drug targets in patient subpopulations with severe unmet needs for a large pharmaceutical company. By incorporating a lab-in-the-loop strategy, its biological modeling and functional screening capabilities were able to confirm and validate these targets within a year, a significant acceleration of the standard discovery timeline. Announcement • Apr 24
Tempus AI, Inc. to Report Q1, 2025 Results on May 06, 2025 Tempus AI, Inc. announced that they will report Q1, 2025 results on May 06, 2025 Recent Insider Transactions Derivative • Apr 02
Chief Operating Officer notifies of intention to sell stock Ryan Fukushima intends to sell 60k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of April. If the sale is conducted around the recent share price of US$48.24, it would amount to US$2.9m. Since June 2024, Ryan's direct individual holding has decreased from 1.11m shares to 960.10k. Company insiders have collectively sold US$288m more than they bought, via options and on-market transactions in the last 12 months. Announcement • Apr 01
Tempus AI, Inc., Annual General Meeting, May 20, 2025 Tempus AI, Inc., Annual General Meeting, May 20, 2025. 
